Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 10, 2014, Pages 3181-3192

  Chi, Ning ^a   Tan, Zhaohui ^a   Ma, Kewei ^a   Bao, Lidao ^b   Yun, Zhizhong ^a  

^a INNER MONGOLIA PEOPLE S HOSPITAL   (China)

^b The Affiliated Hospital of Inner Mongolia Medical University   (China)

Author keywords

IL 6; IL 8; MDSCs; Prostate cancer

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FOLLOW UP; HUMAN; IMMUNE DEFICIENCY; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MYELOID DERIVED SUPPRESSOR CELL; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; SUPPRESSOR CELL; SURVIVAL RATE;

EID: 84910096796     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Ochando JC and Chen SH. Myeloid-derived suppressor cells in transplantation and cancer. Immunol Res 2012; 54: 275-285.
2. Brusa D, Simone M, Gontero P, Spadi R, Racca P, Micari J, Degiuli M, Carletto S, Tizzani A and Matera L. Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: profile comparison. Int J Urol 2013; 20: 971-978.
3. Marigo I, Dolcetti L, Serafini P and Ostrand-Rosenberg S. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008; 222: 162-179.
4. Kong YY, Fuchsberger M, Xiang SD, Apostolopoulos V and Plebanski M. Myeloid derived suppressor cells and their role in diseases. Curr Med Chem 2013; 20: 1437-1444.
5. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ and Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58: 49-59.
6. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP and Gabrilovich DI. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678-689.
7. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, Mier J and Ochoa AC. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65: 3044-3048.
8. Khaled YS, Ammori BJ and Elkord E. Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients. J Immunol Res 2014: 879897.
9. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H and Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008; 118: 3367-3377.
10. Sawant A and Ponnazhagan S. Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis. Cancer Res 2013; 73: 4606-4610.
11. Sawant A, Deshane J, Jules J, Lee CM, Harris BA, Feng X and Ponnazhagan S. Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Res 2013; 73: 672-682.
12. Sawant A, Hensel JA, Chanda D, Harris BA, Siegal GP, Maheshwari A and Ponnazhagan S. Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells. J Immunol 2012; 189: 4258-4265.
13. Ostrand-Rosenberg S and Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499-4506.
14. Gabrilovich DI and Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
15. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R and Finke JH. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15: 2148-2157.
16. Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, Sandoval F, Quintin-Colonna F, Lacerda K, Karadimou A, Badoual C, Tedgui A, Fridman WH and Oudard S. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011; 30: 83-95.
17. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A and Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-241.
18. Taverna G, Giusti G, Seveso M, Hurle R, Colombo P, Stifter S and Grizzi F. Mast Cells as a Potential Prognostic Marker in Prostate Cancer. Dis Markers 2013; 35: 711-720.
19. Ochando JC and Chen SH. Myeloid-derived suppressor cells in transplantation and cancer. Immunol Res 2012; 54: 275-285.
20. Gabitass RF, Annels NE, Stocken DD, Pandha HA and Middleton GW. Elevated myeloid-de rived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011; 60: 1419-1430.
21. Wang Z, Zhang Y, Liu Y, Wang L, Zhao L, Yang T, He C, Song Y and Gao Q. Association of Myeloid-derived Suppressor Cells and Efficacy of Cytokine-induced Killer Cell Immunotherapy in Metastatic Renal Cell Carcinoma Patients. J Immunother 2014; 37: 43-50.
22. Jordan KR, Amaria RN, Ramirez O, Callihan EB, Gao D, Borakove M, Manthey E, Borges VF and McCarter MD. Myeloid-derived suppressor ce-lls are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother 2013; 62: 1711-1722.
23. + T cells from patients with GI malignancy. Cancer Immunol Immunother 2011; 60: 1269-1279.
24. Ben-Baruch A. The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNF-α and Chemokines. Cancer Microenviron 2012; 5: 151-164.
25. Rotondo R, Barisione G, Mastracci L, Grossi F, Orengo AM, Costa R, Truini M, Fabbi M, Ferrini S and Barbieri O. IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. Int J Cancer 2009; 125: 887-893.
26. + cancer stem-like cells in squamous cell carcinoma of the head and neck. Head Neck 2011; 33: 208-215.
27. Lechner MG, Liebertz DJ and Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010; 185: 2273-2284.
28. Finke J, Ko J, Rini B, Rayman P, Ireland J and Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 2011; 11: 856-861.
29. Srivastava MK, Zhu L, Harris-White M, Kar UK, Huang M, Johnson MF, Lee JM, Elashoff D, Strieter R, Dubinett S and Sharma S. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One 2012; 7: e40677.
30. Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J and Berraondo P. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol 2011; 186: 807-815.
31. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, Delgado A, Correa P, Brayer J, Sotomayor EM, Antonia S, Ochoa JB and Ochoa AC. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004; 64: 5839-5849.